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Abstract
Diabetic retinopathy (DR) is a common complication of diabetes, for which hyperglycemia is
a major etiological factor. It is known that retinal glia (Mu¨ller cells) and retinal ganglion cells
(RGCs) are affected by diabetes, and there is evidence that DR is associated with neural
degeneration. Dexamethasone is a glucocorticoid used to treat many inflammatory and
autoimmune conditions, including several eye diseases like DR. Thus, our goal was to study
the effect of dexamethasone on the survival of RGCs and Mu¨ller glial cells isolated from rat
retinas and maintained in vitro under hyperglycemic conditions. The behavior of primary
RGC cell cultures, and of mixed RGC and Mu¨ller cell co-cultures, was studied in hyperglyce-
mic conditions (30 mM glucose), both in the presence and absence of Dexamethasone
(1 μM). RGC and Mu¨ller cell survival was evaluated, and the conditioned media of these cul-
tures was collected to quantify the inflammatory cytokines secreted by these cells using a
multiplex assay. The role of IL-1β, IL-6 and TNFα in RGC death was also evaluated by add-
ing these cytokines to the co-cultures. RGC survival decreased significantly when these
cells were grown in high glucose conditions, reaching 54% survival when they were grown
alone and only 33% when co-cultured with Mu¨ller glia. The analysis of the cytokines in the
conditioned media revealed an increase in IL-1β, IL-6 and TNFα under hyperglycemic con-
ditions, which reverted to the basal concentration in co-cultures maintained in the presence
of dexamethasone. Finally, when these cytokines were added to co-cultures they appeared
to have a direct effect on RGC survival. Hence, these cytokines could be implicated in the
death of RGCs when glucose concentrations increase and dexamethasone might protect
RGCs from the cell death induced in these conditions.
Introduction
Diabetes is a metabolic disease characterized by high glucose concentrations in the blood. One
of the most common complications of this disease is diabetic retinopathy (DR), the leading
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cause of blindness in the population of working-age in developed countries [1]. In the symp-
tomatic phase of DR, key clinical alterations to the vascular system occur that are relevant to
the diagnosis of the disease. Indeed, for many years DR has been considered a microvascular
disease, characterized by increased vascular permeability due to the breakdown of the blood-
retinal barrier (BRB) [2]. Although vascular changes are a classic hallmark of this disorder, sev-
eral observations suggest that microangiopathy is only one aspect of a more widespread retinal
dysfunction.
The concept that neurons as well as capillaries are affected by diabetes is not new. In the
early 1960s, DR was associated with the degeneration of retinal ganglion cells (RGCs) [3, 4]
and indeed, apoptosis of rat retinal neurons is enhanced after chemically induced diabetes [5,
6]. In fact, diabetes-induced changes in retinal neurons and glia may precede the onset of clini-
cally evident vascular injury. Several metabolic impairments have been implicated in the neu-
rodegeneration associated with DR: oxidative stress, characterized by the presence of advanced
glycated end products (AGEs) and nitric oxide (NO); excitotoxicity and excess glutamate
receptor stimulation that provokes the uncontrolled influx of calcium into neurons; and
inflammation, involving the release of chemical mediators and leukostasis [7].
Mu¨ller cells are the principal glia in the retina and they fulfill quite dynamic roles. Mu¨ller
cells extend throughout the thickness of the retina, providing structural stability and maintain-
ing close contact with the majority of retinal neurons [8, 9]. They also provide neurons with
trophic factors and help to maintain retinal homeostasis, potentially promoting cell survival
and repair [10, 11]. Although the physiology of these cells was previously thought to be rather
simple, studies over the past 2 decades have revealed that Mu¨ller cells express a diversity of ion
channels and transporters, that they release a range of cytokines and survival factors, and that
they express receptors for numerous neurotransmitters and growth factors [12, 13]. In fact, it
has been shown that under hyperglycemic conditions, Mu¨ller glial cells contribute to the devel-
opment and progression of diabetes by enhancing caspase-1/IL-1β signaling and mitochon-
drial stress [14, 15]. In addition, Mu¨ller cells markedly up regulate their expression of glial
fibrillary acidic protein (GFAP) early in the course of DR [16], a non-specific response to the
pathophysiological conditions [17].
Dexamethasone (DEX) is a synthetic corticosteroid that displays anti-inflammatory and
immunosuppressive activity. It was first used for an eye-related disease in 1974, when intravi-
treal (IVT) injection was employed to treat experimentally induced Pseudomonas endophthal-
mitis in rabbits [18]. Nowadays, clinical treatment of eye-related conditions with DEX usually
involves administration of slow-release intravitreal implants. These are mostly used to treat
macular edema (ME) and diabetic ME (DME), producing favorable results on visual acuity
(VA) [19–21], as well as in diabetic patients [22–24]. Furthermore, a recent long-term study
into the use of DEX implants showed that it has the potential to not only delay DR progression
but also, it may reduce DR severity over 24 months [25]. Nevertheless, the mechanisms under-
lying the effects of this glucocorticoid are not entirely clear. However, IVT DEX injection is
known to regulate immune responses and to diminish vascular damage by decreasing cell per-
meability in rat models of streptozotocin-induced diabetes [26, 27], possibly acting through
the TNFα pathway [28].
In vitro studies have helped to characterize the retinal damage associated with diabetes. Cell
culture models represent simplified systems to assess the effects of different toxic factors in the
diabetic milieu, such as excess glucose, glutamate and AGEs. We previously showed that pri-
mary cultures of adult rat Mu¨ller glia and RGCs express the same trophic factors and receptors
as they do in vivo [29]. Moreover, Mu¨ller glia cells contact RGCs in co-culture and the factors
secreted by Mu¨ller glia into the medium, can protect pig RGCs from death [30, 31]. Studies on
endothelial and pericyte cell cultures have helped highlight the mechanisms underlying the
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cell damage in diabetes, yet studies on retina neuroglial cultures have been scarce [32]. Thus,
here we set out to study the effect of high levels of glucose, on RGC survival. In order to iden-
tify the role of Mu¨ller glia and their relationship to RGCs, we compared pure RGC cultures
with RGC-Mu¨ller glia co-cultures in different glucose concentrations in vitro. Moreover, to
better understand the benefits that DEX produces in DR, we also examined its effect on puri-
fied rat RGCs, as well as on RGCs co-cultured with Mu¨ller glia maintained under hyperglyce-
mic conditions. The role of inflammation in this process was also assessed by measuring the
cytokines that accumulate in the medium of these cultures, thereby identifying cytokines that
might protect RGCs from the toxic effects of hyperglycemia.
Materials and methods
Retinal cell cultures
This study was carried out in strict accordance with the recommendations in the Guide for the
Care and Use of Laboratory Animals. The experimental protocol met European (2010/63/UE)
and Spanish (RD53/2013) regulations for the protection of experimental animals, and it was
approved by the Ethical Committee for Animal Welfare of the University of Basque country.
RGCs and Mu¨ller glia were isolated from adult female Sprague-Dawley rats, humanely sacri-
ficed by exposure to CO2, establishing two types of culture: (1) Pure RGC cultures; and (2) co-
culture of RGCs and Mu¨ller glial cells. The retinas were dissected and dissociated enzymati-
cally with papain (Worthington Papain Dissociation kit, Worthington Biochemical Lakewood,
NJ, USA) for 90 (RGCs) or 30 min (co-cultures), according to the manufacturer’s instructions.
The dissociated cells were recovered by centrifugation and the RGC cultures were prepared as
described previously [31]. Briefly, the dissociated cells were passed through an ovomucoid
inhibitor-albumin gradient, where more RGCs than Mu¨ller cells pass due to their larger size
(this step was excluded when preparing the co-cultures). While this gradient does not purify
RGCs to homogeneity, there is only minimal contamination of other cells (data not shown).
After purification, the cells were seeded on 13 mm diameter poly-L-lysine (10 g/ml: Sigma–
Aldrich, St. Louis, MO, USA) and laminin (10 g/ml: Sigma–Aldrich, St. Louis, MO, USA)
coated coverslips in 24-well plates. The RGCs were seeded at 105 viable cells per well and the
co-culture of RGCs and Mu¨ller glia were established at 6x106 viable cells per well (as deter-
mined by trypan blue test).
Different media were used for each culture type, containing 1% L-glutamine (2 mM: Life
Technologies, Carlsbad, CA, USA) and 0.1% gentamicin (50 mg/ml: Life Technologies, Carls-
bad, CA, USA): Neurobasal-A medium supplemented with 2% B27 (Life Technologies, Carls-
bad, CA, USA) for RGC cultures; and B27 supplemented Neurobasal-A medium with 10%
FBS (Fetal Bovine Serum: Life Technologies, Carlsbad, CA, USA) for RGC and Mu¨ller mixed
cell cultures. In addition, each culture type was maintained under distinct conditions: i) Con-
trol (untreated); ii) 1 μM DEX (Sigma Aldrich, Saint Louise, MO, USA); iii) 10 mM Glucose;
iv) 30 mM Glucose; and v) 30 mM Glucose + 1μM DEX. The different conditions were
employed from the start of the culture and the medium was changed every 48 hours. At least 4
replicates of each culture type were performed in triplicate. In addition, a further control
involved maintaining the cells in the presence of 30 mM mannitol to demonstrate that the
osmolarity of the glucose solution did not affect the results. Exposure to mannitol induced no
significant changes (results not shown).
Immunocytochemistry
After 6 days in culture, the cells were fixed in cold methanol and washed with PBS (phosphate
buffered saline, pH 7.0). After blocking non-specific antigens with blocking buffer (3% BSA
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and 0.1% Triton X-100 in PBS), the cells were incubated with the following primary antibodies
at a dilution of 1:2,000: a mouse anti-βIII-tubulin antibody (Promega Madison, WI, USA) as a
specific RGC marker and a rabbit anti-Vimentin antiserum (Abcam, Cambridge, England) as
a specific marker of Mu¨ller cells. After washing the cells, antibody binding was detected with
an anti-mouse Alexa Fluor 488 and an anti-rabbit Alexa Fluor 555 (Life Technologies, Carls-
bad, AC, USA) secondary antibodies, diluted 1:1,000. In addition, the cell nuclei were labeled
with DAPI (Life Technologies, Carlsbad, AC, USA) at a dilution of 1:10,000.
Cell quantification
The same number of cells were seeded per plate for each condition and in each experiment,
and the cultures were analyzed on an epifluorescence microscope (Zeiss, Jena, Germany) cou-
pled to a digital camera (Zeiss Axiocam MRM, Zeiss, Jena, Germany). The total number of
RGCs and Mu¨ller cells per coverslip was quantified using the specific markers indicated. The
Mu¨ller cell counts were normalized to the number of cells grown in the control conditions,
considered as 100% survival. The RGCs and Mu¨ller cells in co-cultures were counted in images
obtained with a filter specific for only one of the antibody markers. However, since there may
be an overlap with vimentin stained cells, the semi-automatic Zen software (Zeiss, Jena, Ger-
many) was used to count the number of nuclei stained with DAPI, taking into consideration
the limits of the axis of the nuclei of Mu¨ller cells to achieve more accurate measurements. For
that purpose, we used a specific macro designed to specifically measure the limits of the axes
(50–200 μm), which was corrected manually for each image. At least 4 complete coverslips and
3 independent experiments were analyzed for each experimental condition.
Multiplex cytokine assays
After 6 days in culture, conditioned medium (supernatant) was collected for each experimental
condition, filtered and the cytokines present were quantified with a Q-Plex multiplex enzyme-
linked immunosorbent assay (Q-Plex Rat Cytokine—Inflammation (9-Plex): Quansys Biosci-
ence, Logan, UT, USA). The presence of 9 cytokines in 150 μl of each sample was assessed in a
98-well Q-Plex plate according to the manufacturer´s instructions: IL-1α, IL-1β, IL-2, IL-4, IL-
6, IL-10, IL-12, IFNγ and TNFα. The standards were measured in duplicate and the cytokine
concentrations were calculated using a standard curve. Four replicates were assessed for each
sample and arithmetic averages were calculated. The data were normalized per 10,000 cells.
Cell cultures analysis adding IL-1β, IL-6 and TNFα
The direct effects of the IL-1β, IL-6 and TNFα cytokines were assessed in RGC-Mu¨ller cells
co-cultures. We used the combination of these cytokines because they were found to be over-
expressed in the supernatant of the cultures treated with 30 mM glucose. Six different condi-
tions were analyzed: (1) Control (Neurobasal-A medium supplemented with 2% B27 and 10%
FBS); (2) 1 μM DEX; (3) a mix of the three cytokines (IL-1β, IL-6 and TNFα: Sigma-Aldrich,
St. Louis, MO, USA) at 10 ng/ml, as suggested by the supplier in the data sheet; (4) the cytokine
mix at the concentrations in the conditioned medium identified by the multiplex cytokine
assay: 16.75 pg/ml for IL-1β, 435 pg/ml for IL-6 and 32.1 pg/ml for TNFα; and (5) and (6) the
mixtures of cytokines at both concentrations, respectively plus 1 μM DEX. The cytokines were
added to the culture from the fourth (when the culture was stabilized) to the sixth day of cul-
ture (a 48 hour treatment), and after the sixth day the culture was fixed, immunostained and
the cells were quantified as indicated above.
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Statistical analysis
Statistical analyses were carried out using the IBM SPSS Statistical software (v. 21.0), calculat-
ing the mean and standard error for each condition. The data from the different experimental
conditions were compared using an analysis of variance (ANOVA), followed by the Tukey or
Games-Howell test depending on the homogeneity of the variances. Differences were consid-
ered significant for all tests at p< 0.05.
Results
RGC cultures
To analyze how hyperglycemia affects RGC survival, the RGCs in primary cultures were
counted in the control conditions and following the different experimental manipulations
(Fig 1). When considered relative to the controls (considered as 100% survival: Table 1, see
Table 1 in S1 File for the raw data), maintaining RGCs in the presence of 1 μM DEX or 10 mM
glucose had no significant effect on cell survival (p>0.05). By contrast, RGC survival dimin-
ished significantly relative to the controls in the presence of 30 mM glucose (54.64 ± 6.74%,
p<0.05). Interestingly, this impairment in RGC survival in the presence of 30 mM glucose was
Fig 1. RGC cultures. Images of RGC cultures in control conditions (A), in the presence of 30 mM glucose (B) or 30
mM glucose plus 1μM dexamethasone (C). The RGCs were labeled with an antibody against Beta III-Tubulin (red)
and with DAPI for nuclear counterstaining. (D) Percentage of RGCs surviving in the different conditions. A loss of
RGC survival is evident in the presence of 30 mM glucose, while the presence of 1 μM dexamethasone rescued the
RGCs from death, reverting survival to the basal values. The data are presented as the mean + SEM. Scale
bar = 100 μm, �p<0.05.
https://doi.org/10.1371/journal.pone.0207913.g001
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partially recovered by adding 1 μM DEX to the cell cultures (79.53 ± 12.24% cell survival), a
survival rate that was not significantly different to that recorded in the controls. However,
when RGC survival in the presence of 30 mM glucose was compared with that in the presence
of 30 mM glucose and DEX, there was no clear difference in survival (p = 0.477, see S2 File for
statistical analysis: Fig 1). Hence, DEX appeared to at least partially ameliorate the effect of
high glucose on RGC survival in culture.
Co-cultures
Given the supportive and neuroprotective properties of Mu¨ller cells, we assessed the effects of
glucose and DEX on the survival of RGCs when they were co-cultured with Mu¨ller cells. Tak-
ing the control cultures as 100%, 67.35 ± 9.41% (p<0.05) of the RGCs survived 6 days in co-
culture in the presence of 10 mM glucose, and this figure dropped to 33.10 ± 4.03 (p<0.05) in
the presence of 30 mM glucose (Table 2, see Table 2 in S1 File for the raw data). However, this
significant decrease in cell survival was rescued by adding 1 μM DEX to the cultures, in the
presence of which the survival of RGCs was no different to that in the control cultures. Indeed,
RGC survival in the presence of 30 mM glucose improved significantly when DEX was added
to the co-cultures (p = 0.001: Fig 2, see S3 File for the statistical analysis).
Indeed, the survival of Mu¨ller cells decreased significantly in the co-cultures in the presence
of both 10 mM (26.15 ± 8.35%, p<0.05) and 30 mM glucose (19.52 ± 4.84% relative to the con-
trols, p<0.05: Table 3 and S1 File for the raw data). However, dexamethasone (1 μM) had no
significant effect on the survival of Mu¨ller cells in high glucose media (36.82 ± 8.01%), with no
differences in cell number relative to the co-cultures maintained in the presence of 30 mM glu-
cose alone (p = 0.384) and with significantly fewer Mu¨ller cells than in the control conditions
(p<0.05: Fig 2, see S4 File for the statistical analysis).
Table 1. Survival of RGCs in pure culture of RGCs.
EXPERIMENTAL CONDITION % of RGCs n p value compared to the control
Control 100 ± 11.46 12 -
1 μM Dexamethasone 99.29 ± 7.54 12 1.000
10 mM Glucose 85.30 ± 11.51 12 0.846
30 mM Glucose 54.64 ± 6.74 10 0.032
30 mM Glucose + 1 μM Dexamethasone 79.53 ± 12.24 12 0.618
The data are expressed as the proportion of surviving cells (mean + SEM), evaluated by ANOVA followed by the Tukey or Games-Howell test depending on the
homogeneity of variances.
https://doi.org/10.1371/journal.pone.0207913.t001
Table 2. Survival of RGCs in co-culture.
EXPERIMENTAL CONDITION % of RGCs n p value compared to control
Control 100 ± 7.37 12 -
1 μM Dexamethasone 105.65 ± 8.22 10 0.986
10mM Glucose 67.35 ± 9.41 10 0.040
30 mM Glucose 33.10 ± 4.03 11 0.000
30 mM Glucose + 1 μM Dexamethasone 80.04 ± 9.66 11 0.366
The data are expressed as the percentage of surviving cells (mean ± SEM), evaluated using ANOVA followed by the Tukey or Games-Howell test depending on the
homogeneity of variances.
https://doi.org/10.1371/journal.pone.0207913.t002
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Cytokine assay
The amounts of the inflammatory cytokines in the conditioned media obtained from the
two types of cultures were analyzed for each experimental condition, quantifying the follow-
ing cytokines: IL-1α, IL-1β, IL-2, IL-4, IL-6, IL-10, IL-12, IFNγ, and TNFα (Table 4, see
Table 4 in S1 File for raw data). With pure RGC cultures, no reliable data were obtained due
to the small number of cells in this type of culture (approx. 100 cells per coverslip in the con-
trol conditions).
In the co-cultures, the presence of 30 mM glucose provoked a significant increase in three
of the nine cytokines evaluated, with the concentration of IL-6 increasing 172% (2.72 fold,
1609.22 ± 250.89 pg/ml, p<0.05) relative to the control condition (589.73 ± 31.49 pg/ml), that
of TNFα increasing 81.5% (1.80 fold, 118.61 ± 7.78 pg/ml, p<0.05) relative to the control
Fig 2. Co-cultures of RGCs and Mu¨ller cells. RGCs were labeled with an antibody against Beta III-Tubulin (red) and
Mu¨ller cells with a Vimentin antibody (green). Note the increased survival of RGCs in the presence of dexamethasone
when co-cultures are maintained in the presence of 30 mM Glucose (compare B and E to C and F). (G) RGC survival
in the different conditions. RGC survival decreases on exposure to 10 mM (67.35 ± 9.41%, �p<0.05) or 30 mM glucose
(33.10 ± 4.03%, �p<0.05), while the presence of 1 μM Dexamethasone enhances the survival of RGCs, reverting it
to control levels. (H) The proportion of Mu¨ller cells was significantly affected by exposure to 30 mM glucose
(19.52 ± 4.84%,�p<0.05), yet this decrease in Mu¨ller cell survival was not reversed in the presence of 1 μM
dexamethasone. The data represent the mean ± SEM. Scale bar = 100 μm, �p<0.05.
https://doi.org/10.1371/journal.pone.0207913.g002
Table 3. Survival of Mu¨ller cells in co-culture.
EXPERIMENTAL CONDITION % of Mu¨ller cells n p value compared to control
Control 100 ± 4.78 10 -
1 μM Dexamethasone 78.84 ± 10.58 9 0.408
10mM Glucose 26.15 ± 8.35 8 0.000
30 mM Glucose 19.52 ± 4.84 10 0.000
30 mM Glucose + 1 μM Dexamethasone 36.82 ± 8.01 10 0.000
The data are expressed as the relative cell survival (mean + SEM), analyzed by ANOVA followed by the Tukey or Games-Howell test depending on the homogeneity of
variances.
https://doi.org/10.1371/journal.pone.0207913.t003
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(65.60 ± 10.75 pg/ml), and while IL-1β was undetectable in the control conditions, its concen-
tration increased to 61.89 ± 8.23 pg/ml (p<0.05) in these high glucose conditions. When DEX
was added to the cultures maintained in the presence of 30 mM glucose, the concentration of
these three cytokines (IL-6, TNFα and IL-1β) reverted to the control values (Fig 3).
IL-2 was also undetectable in control conditions, yet the concentration increased to
45.74 ± 37.57 pg/ml in the presence of high glucose. Similarly, the small quantities of IL-10
that were detected in control cultures (5.89 ± 0.18 pg/ml) also increased significantly in the
presence of high glucose (11.55 ± 0.97 pg/ml, p<0.05). Importantly, DEX did not alter the
accumulation of these two cytokines in the presence of 30 mM glucose. No significant changes
were evident in the accumulation of the other cytokines analyzed (IL-1α, IL-4, IL-12 and
IFNγ) between any of the different experimental conditions relative to the controls (Table 1,
see S5 File for statistical analysis).
Effect of IL-1β, IL-6 and TNFα on co-cultures
The effect of IL-1β, IL-6 and TNFα on co-cultures was analyzed to confirm the role of these
cytokines in RGC death. In addition, the effect of DEX in combination with these three cyto-
kines was also assessed (Fig 4).
With the control cultures as a reference for 100% survival (Table 5, see Table 5 in S1 File for
the raw data), 27.78 ± 5.96% (p<0.05) of the RGCs survive after 6 days in culture in the pres-
ence of the three cytokines (10 ng/ml) for 48 hours. In the presence of lower concentrations of
IL-1β, IL-6 and TNFα (pg/ml) for the same period, 46.89 ± 2.88% of RGCs survive (p<0.05).
However, the presence of DEX at either concentration of the cytokines failed to rescue RGCs
from death, and the survival rates of RGCs in the presence of DEX were 35.91 ± 5.81% and
28.62 ± 5.13% for the ng/ml and pg/ml concentrations of cytokines, respectively. These rates
Table 4. Concentration of cytokines in the different conditioned media obtained from RGC and Mu¨ller cell co-cultures (data normalized per 10,000 cells).
Cytokine Control 1 μM Dexamethasone 10 mM Glucose 30 mM Glucose 30 mM Glucose + 1 μM Dexamethasone
IL-1α 40.55±17.36 6.31±6.31 0±0 18.77±11.06 50.34±24.32
IL-1β 0±0 0±0 0±0 61.89±8.23 0±0
IL-2 0±0 0±0 0±0 45.74±37.57 45.86±34.16
IL-4 13.85±0.49 3.44±2.89 3.77±2.57 2.99±1.88 2.56±2.56
IL-6 589.73±31.49 178.92±45.77 764.61±76.95 1209.22±250.89 510.17±96.18
IL-10 5.89±0.18 4.23±0.45 5.89±0.71 11.45±0.97 9.30±0.53
IL-12 15.78±9.26 13.09±7.80 16.40±9.91 14.38±14.17 30.08±9.66
IFNγ 69.39±24.18 97.35±5.61 146.95±13.34 15.15±15.15 146.85±52.15
TNFα 65.60±10.75 18.83±6.66 62.55±4.01 118.61±7.78 59.07±13.08
The data are expressed as pg/ml (mean + SEM).
https://doi.org/10.1371/journal.pone.0207913.t004
Fig 3. IL-1β, IL-6 and TNFα levels in the co-cultures. The changes in the three most significant cytokines of the 9
analyzed are shown: the IL-1β (A), IL-6 (B) and TNFα (C) in the conditioned medium of the RGC and Mu¨ller cell co-
cultures under different conditions. The amounts of these cytokines increases in the presence of 30 mM glucose, yet
they revert to the control levels when dexamethasone (1 μm) was added (�p<0.05).
https://doi.org/10.1371/journal.pone.0207913.g003
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were significantly lower than in the control conditions (p<0.05) but they were not significantly
different to when these cultures were maintained in the presence of these cytokines alone
(p = 0.993 and p = 0.811 for the ng/ml and pg/ml cytokine concentrations, respectively: see S6
File for the statistical analysis).
Mu¨ller cell survival in the co-cultures was not affected by the presence of either concentra-
tion of the cytokines, with 98.88 ± 17.68% Mu¨ller cell survival in the presence of ng/ml cyto-
kine concentrations and 80.11 ± 18.49% with the pg/ml concentrations of cytokines, showing
no differences relative to the controls (Table 6, see Table 6 in S1 File for raw data). Similarly,
DEX (1 μM) had no significant effect on the survival of Mu¨ller cells at either cytokine concen-
tration: 77.84 ± 21.83% Mu¨ller cell survival in the presence of ng/ml cytokines; and
96.02 ± 33.59% in pg/ml concentrations of the cytokines (p = 0.972 by ANOVA, meaning that
there are no significant differences between the groups: see S7 File for the statistical analysis).
Fig 4. Effect of IL-1β, IL-6 and TNFα on the co-cultures. The RGCs were labeled with an antibody against Beta
III-Tubulin (red) and the Mu¨ller cells with an antibody against Vimentin (green). Note the decreased RGC survival in
the presence of the cytokines at both concentrations (C, E) and in combination with dexamethasone (D, F). (G) The
percentage of RGCs surviving in the different conditions. (H) There were no changes in the proportion of Mu¨ller cells
under each of the experimental conditions. The data represent the mean ± SEM: �p<0.05. Scale bar = 100 μm.
https://doi.org/10.1371/journal.pone.0207913.g004
Table 5. Survival of RGCs in co-culture in presence of cytokines.
EXPERIMENTAL CONDITION % of RGCs n p value compared to control
Control 100 ± 11.56 3 -
1μM Dex 86.62 ± 18.22 5 0.947
IL-1β, IL-6, TNFα (ng/ml) 27.78 ± 5.96 4 0.003
IL-1β, IL-6, TNFα (ng/ml) + 1μM Dex 35.91 ± 5.81 4 0.009
IL-1β, IL-6, TNFα (pg/ml) 46.89 ± 2.88 4 0.036
IL-1β, IL-6, TNFα (pg/ml) + 1μM Dex 28.62 ± 5.13 4 0.003
The data are expressed as the percentage of surviving cells (mean ± SEM), assessed by ANOVA followed by the Tukey or Games-Howell test depending on the
homogeneity of variances.
https://doi.org/10.1371/journal.pone.0207913.t005
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Discussion
Hyperglycemia is considered a major factor in the etiology of DR. Like the brain, the retina
primarily utilizes glucose to synthesize ATP and retinal neurons preferentially metabolize glu-
cose rather than lactate in vitro [33]. While RGCs obtain some glucose directly, they also
obtain glucose through astrocytes [34] or Mu¨ller glial cells [35].
As shown here, retinal neurons are particularly susceptible to long-term hyperglycemia. In
our experimental set-up, a high concentration of glucose (30 mM) induces RGC death in cul-
ture, an effect that is partially reversed by DEX, raising the possibility that RGCs themselves
could secrete pro-inflammatory agents that act as autocrine effectors and that possibly induce
cell death. We analyzed the secretion of pro-inflammatory cytokines by RGCs, yet the test
used was not sufficiently sensitive given the small number of pure RGCs that can be cultured.
Neurons are typically examined as targets for cytokine signaling, with various cytokine recep-
tors expressed on neural membranes [34, 35]. However, neurons and specifically RGCs, are
also a source of releasable cytokines including: Interleukin 3 (IL-3), TNF-α, CXCL9, VEGF, L-
selectin, IL-4, GM-CSF, IL-10, IL-1Rα, MIP and CCL20 [36–38]. Indeed, high levels of glucose
activate the overexpression of pro-inflammatory cytokines (IL-1β and IL-18) by RGCs [39],
and the expression of TLR-2 and TLR-4 by RGCs, enhancing the secretion of pro-inflamma-
tory factors [40–42]. Although DEX partially rescues RGCs exposed high glucose and we
believe that inflammatory pathways could be implicated in this effect, it is possible that other
mechanisms are also at play. Many factors could be involved in the death of RGCs associated
with hyperglycemia and indeed, such a high-glucose environment could enhance oxidative
stress and mitochondrial dysfunction, thereby accelerating the apoptosis of RGCs via caspase-
3 activation [39, 41, 43]. It is noteworthy that because of the high-energy demand of RGCs,
they have large numbers of mitochondria [44, 45], and consequently, it is not surprising that
they are particularly vulnerable to any mitochondrial dysfunction in DR. In addition, the
expression of the high mobility group box 1 (HMGB-1), a chromatin protein that can promote
angiogenesis and induce inflammation, may also be implicated in hyperglycemic RGC death
[46].
RGCs are more adversely affected by high glucose concentrations (30 mM) when they are
co-cultured with Mu¨ller cells than when growing in pure culture. Furthermore, at 10 mM glu-
cose RGCs are significantly affected when they are co-cultured with Mu¨ller cells, with the sur-
vival of the latter also affected by high glucose conditions. Mu¨ller cell death following exposure
to high glucose conditions (25–30 mM glucose) has been described elsewhere [47, 48], and it
has potentially been related to AKT inhibition [49]. Indeed, when rat retinal Mu¨ller glia were
exposed to 25 mM glucose for 72 h culture, Akt was inactivated and apoptosis induced. More-
over, hyperglycemia stimulates GAPDH accumulation in the nucleus of retinal Mu¨ller cells, in
association with the apoptosis of these cells. [47, 50]. It is possible that Mu¨ller cell death could
Table 6. Survival of Mu¨ller cells in co-culture in presence of cytokines.
EXPERIMENTAL CONDITION % of Mu¨ller cells n
Control 100 ± 27.63 4
1μM Dex 88.08 ± 25.06 3
IL-1β, IL-6, TNFα (ng/ml) 98.88 ± 17.68 4
IL-1β, IL-6, TNFα (ng/ml) + 1μM Dex 77.84 ± 21.83 3
IL-1β, IL-6, TNFα (pg/ml) 80.11 ± 18.49 4
IL-1β, IL-6, TNFα (pg/ml) + 1μM Dex 96.02 ± 33.59 3
The data represent the percentage of surviving Mu¨ller cells (mean + SEM).
https://doi.org/10.1371/journal.pone.0207913.t006
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also affect RGCs, accentuating the deleterious effect of glucose on RGCs. Moreover, Mu¨ller
cell gliosis could damage RGCs under conditions of stress. Gliosis of Mu¨ller cells can have
both cytoprotective and cytotoxic effects on retinal neurons depending on the extent of glial
activation [8]. It is already known that diabetes induces abnormalities in retinal Mu¨ller cells,
including increased GFAP expression, reduced glutamine synthetase and decreased glutamate
transporter activity [51]. It is well established that Mu¨ller cells become activated in DR [52–54]
but nevertheless, the contribution of Mu¨ller cells to DR remains unclear [47].
RGC death caused by exposure to high glucose might be provoked by the up-regulation of
secreted pro-inflammatory factors [40, 46] and several studies confirm the relevance of Mu¨ller
glia in the provision of inflammatory factors after activation, such as cytokines. Mu¨ller glia are
the main source of many cytokines and other inflammatory factors in the gliotic retina in vitro
[55], which may serve to protect Mu¨ller cells from diabetic insult, and consequently, retinal
neurons. The damage produce by these factors in DR might be only a secondary effect [56]. In
DR, Mu¨ller cells exhibit a reactive phenotype characterized by the activation of inflammatory-
related genes [8]. The proinflammatory response of Mu¨ller glia has been associated to the acti-
vation of the receptor for advanced glycation end-products (RAGE) and its ligand S100B,
which stimulate cytokine production through MAPK signaling pathways [57]. The accumula-
tion of these inflammatory mediators is thought to enhance early neuronal cell death in the
retina [55], which would explain the contribution of Mu¨ller cells to the decrease in RGC sur-
vival in our co-cultures.
Inflammation is considered to play a critical role in the progression of diabetic complica-
tions, including DR [37]. Glucocorticoids like DEX are powerful anti-inflammatory com-
pounds. They are steroid hormones that cross the cell membrane and interact with
intracellular glucocorticoid receptors (GCRs). The distribution of GCRs in the retina is highly
conserved and as they are almost exclusively restricted to Mu¨ller glia, and GCRs might
enhance survival indirectly through these glial cells [58, 59]. The data obtained here show that
when RGCs are exposed to high glucose, more RGCs die when they are in contact with Mu¨ller
glia than when they grow alone. However, DEX rescues these cells in both situations, which
indicates it has a direct effect on RGCs. Glucocorticoids like DEX can induce endotoxin toler-
ance, acting as negative regulators of TLR4 signaling, and efficiently downregulating the pro-
duction of pro-inflammatory cytokines [45].
The anti-inflammatory properties of DEX may rescue RGCs from death and thus, our
results suggest that inflammation plays a critical role in the RGC death provoked by high glu-
cose concentrations in vitro. To determine the effect of DEX on RGC survival in such high glu-
cose conditions and its critical influence on inflammation in DR, the implication of cytokines
in the inflammatory response caused by hyperglycemia was analyzed in conditioned medium.
The levels of IL-1β, IL-6 and TNFα increase significantly in co-cultures maintained in the pres-
ence of high glucose, while DEX reverts the concentration of these cytokines to basal values.
Hence, these cytokines may be involved in RGC death, since RGC survival decreases when the
concentration of these cytokines augments.
When we cultured RGCs and Mu¨ller cells with the three cytokines and in the presence of
DEX, IL-1β, IL-6 and TNFα appear to be directly involved in RGC death. However, DEX
could not rescue RGCs maintained in the presence of the cytokines suggesting it has no effect
once they are secreted into the medium. Thus, DEX might be implicated in dampening the
release or expression of these cytokines by Mu¨ller glia and RGCs. Glucocorticoids like DEX,
can exert multiple anti-inflammatory effects, even directly interacting with the transcriptional
machinery through the TLRs expressed by Mu¨ller cells [60] and RGCs [39]. TLR signaling
pathways may be important targets for DEX [61] and thus, DEX could activate the TLR signal-
ing that inhibits the inflammatory response.
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IL-1β, IL-6 and TNFα are pro-inflammatory cytokines, and IL-6 is a potential mediator of
intraocular inflammation [38], inducing numerous physiological and immune responses [52].
Mu¨ller glia cells release several inflammatory factors and cytokines [55], and some cytokines
are even known to stimulate the production of other cytokines by Mu¨ller glia [62], including
IL-6 [62], IL-1β [53] and TNFα [54] in response to different stressors. Moreover, Mu¨ller cells
are a major source of retinal IL-1β [19, 20, 63, 64] and they also secrete TNFα, facilitating the
apoptotic death of RGCs in response to damage [65]. Together, these findings suggests that in
hyperglycemic conditions, Mu¨ller cells could enhance RGC death in co-cultures by releasing
these cytokines, while DEX can reverse this effect by recovering basal cytokine levels. High glu-
cose conditions also increase the concentrations of IL-2 and IL-10, yet DEX does not decrease
the production of these cytokines. Increased IL-2 has been seen in experimental models of DR
[65], while IL-10 is an anti-inflammatory cytokine [66], which may be related to protection
against the development of late diabetic complications [67]. Indeed, DEX induces the release
of anti-inflammatory cytokines like IL-10 less than that of pro-inflammatory cytokines [68].
The death of Mu¨ller cells in hyperglycemic conditions may be related to other mechanisms
not assessed here. This would be consistent with the failure of DEX to rescue these cells and
their insensitivity to exogenous cytokine addition. Such effects may be associated with
Fig 5. Scheme showing the possible mechanisms active in Mu¨ller cell and RGC co-cultures exposed to high
glucose, dexamethasone and cytokines. (A) High glucose (30 mM) has a detrimental effect on Mu¨ller glia (green) and
RGCs (red). Cytokine secretion may be responsible for the effects on cell survival observed. (B) When DEX is added in
a high glucose environment, the concentration of cytokines decreases and consequently, RGC survival is enhanced.
However, Mu¨ller cells were not rescued by DEX. (C) When cytokines are added to the media, RGCs survival is
compromised while that of Mu¨ller cells is not affected, either in the presence or absence of DEX. We conclude that
DEX could inhibit cytokine release, and that RGCs and Mu¨ller cells may exhibit distinct sensitivity to the action of
cytokines. More experiments will be necessary to elucidate the precise mechanism(s) that relate high glucose-induced
cytokine secretion and retinal cell survival.
https://doi.org/10.1371/journal.pone.0207913.g005
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perturbations to essential functions, such as neurotransmitter recycling, the control of gluta-
mate toxicity, a redistribution of ions or the regulation of metabolic pathways, among others
[10, 56]. For example, the expression of Kir4.1 (an inwardly rectifying potassium channel) is
altered by TNF-α in the Mu¨ller cells of diabetic patients [67]. Other cytokines not considered
here could also alter adaptor molecules like Act 1, thereby provoking damage [68]. Also, in a
context of diabetes-induced retinal gliosis, long non-coding RNAs affect Mu¨ller cell viability
and proliferation [69]. Indeed, oxidative stress suppresses glutamine synthetase activity in dia-
betic conditions, mediated by the thioredoxin-interacting protein, TXNIP [70]. Additionally,
Glutaredoxin, an enzyme that catalyzes the deglutationation of key targets like IKK (a kinase
that activates NF-κβ receptors), appears to be associated with elevated IL-6 secretion in vitro
[71].
Our findings may have therapeutic implications. DME is the main cause of vision loss in
patients with DR [69] and the most common first line therapy for DME is IVT injection of
anti-VEGF agents [70, 71]. Another therapeutic option for DME is the injection of Ozurdex,
an DEX slow release IVT implant that administers this drug over 4 to 6 months. Thus, DEX
may also protect RGCs in the context of DR when used in a slow release formula.
In summary (Fig 5), we conclude that high concentrations of glucose (30 mM) decrease the
survival of RGCs when cultured alone or with Mu¨ller glia. This effect could be at least partially
due to the secretion of cytokines, in particular L-1β, IL-6 and TNFα, which were elevated in
the milieu after glucose treatment. The influence of these cytokines was confirmed when they
were added exogenously. Moreover, DEX prevents RGC death in hyperglycemic conditions, at
least partially by dampening the release of cytokines.
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